Picture [iito] Life Science Business Portals Media Data 2022 650x100px
Employment/Membership › Details

Ysios Capital–Harth T: management, 202203– Principal before Senior Asociate at Gimv


Period Period 2022-03-04
Organisations Organisation Ysios Capital Partners SGECR S.A.
  Group Ysios Capital (Group)
  Organisation 2 Gimv N.V. (Euronext: GIMB)
  Group Gimv (Group)
Products Product venture capital
  Product 2 BIOTECH

Ysios Capital. (3/4/22). "Press Release: Ysios Capital Strengthens Its Team with the Appointment of Thomas Harth as Principal Thomas Harth". San Sebastián & Barcelona.

> Thomas Harth joins Ysios Capital as Principal after 5 years at Gimv NV, Belgium.

> This key addition will strengthen the Ysios Capital team, which is currently investing its fund Ysios BioFund III.

Ysios Capital, a European life sciences venture capital firm, today announced that it has appointed Thomas Harth as Principal.

Thomas will be responsible for sourcing and evaluating investment opportunities. As Principal, he will also represent Ysios as member of the board of directors of its portfolio companies.

Thomas holds a master’s degree in Bioengineering and Applied Economics, both from the University of Ghent. Previously, Thomas was Senior Associate at Gimv within the Health & Care team working out of the Antwerp office. He was focused on early-stage Life Sciences investments. Thomas co-led the investments in Anjarium biosciences and Kinaset Therapeutics and was involved with portfolio companies Fire1, ONWARD (Euronext – ONWD), Biotalys (Euronext – BTLS), JenaValve, and Breath Therapeutics (sold to Zambon).

“We have worked with Thomas in several deals during his time at Gimv and have been impressed by his analytical and negotiation skills. We’re delighted to welcome him on board in our Barcelona office. Attracting international talent is key to building a diverse and skilled team able to identify pioneering science worldwide and transform capital into medical breakthroughs.” comments Joël Jean-Mairet, Managing Partner at Ysios Capital.

“I am pleased to join Ysios Capital team, which is a strong and recognized player in Europe and has a key role in the booming Spanish biotech sector. I look forward to contributing to the growth and internationalization of Ysios Capital and support the continuation of its successful track record”, says Thomas Harth, Principal at Ysios Capital.

After a very active 2021, closing an oversubscribed €216M fund, 3 NASDAQ IPOs, and Sanifit’s landmark acquisition by Vifor Pharma, Ysios Capital is now focused on managing its portfolio companies as well as completing the portfolio of Ysios BioFund III.

About Ysios Capital

Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs. Ysios Capital was founded in 2008 and has over $450 million in assets under management through its three funds.

For more information, please visit

Record changed: 2022-05-23


Picture [iito] No Tracking 650x100px

More documents for Ysios Capital (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top